William Blair analyst Myles Minter has reiterated their bullish stance on DNLI stock, giving a Buy rating yesterday.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Myles Minter has given his Buy rating due to a combination of factors including Denali Therapeutics’ promising pipeline and strategic advancements. The company’s recent R&D day highlighted their innovative blood-brain barrier TransportVehicle (TV) technology, which is poised to revolutionize treatments for neurological disorders. The positive market reaction, evidenced by a 6% increase in shares, underscores investor confidence in Denali’s potential.
Minter is optimistic about the near-term launch of tividenofusp alfa (tivi) for Hunter syndrome, with expectations of strong commercial synergies from follow-on products like DNL126 for Sanfilippo syndrome type A. Despite some setbacks, such as the clinical hold on the Pompe program, Denali’s strategic D3X3 initiative aims to deliver significant value through its TV platform. With potential billion-dollar sales from tivi and DNL126, and promising developments in Alzheimer’s treatments, Minter sees multiple avenues for value growth, justifying the Buy rating.
In another report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a $29.00 price target.